195 related articles for article (PubMed ID: 26428357)
1. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.
Sechaud R; Machineni S; Tillmann HC; Hara H; Tan X; Zhao R; Ren S; Hou J
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):723-731. PubMed ID: 26428357
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
[TBL] [Abstract][Full Text] [Related]
7. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Bartels C; Looby M; Sechaud R; Kaiser G
Br J Clin Pharmacol; 2013 Dec; 76(6):868-79. PubMed ID: 23506208
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).
Sechaud R; Renard D; Zhang-Auberson L; Motte Sde L; Drollmann A; Kaiser G
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):118-28. PubMed ID: 22257577
[TBL] [Abstract][Full Text] [Related]
9. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
[TBL] [Abstract][Full Text] [Related]
10. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
12. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
Dumitras S; Sechaud R; Drollmann A; Pal P; Vaidyanathan S; Camenisch G; Kaiser G
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):771-9. PubMed ID: 24040847
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
15. Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults.
Dorinsky P; DePetrillo P; DeAngelis K; Trivedi R; Darken P; Gillen M
Clin Ther; 2020 Apr; 42(4):634-648. PubMed ID: 32253054
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
[TBL] [Abstract][Full Text] [Related]
17. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
[TBL] [Abstract][Full Text] [Related]
18. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
Chapman KR; Beeh KM; Beier J; Bateman ED; D'Urzo A; Nutbrown R; Henley M; Chen H; Overend T; D'Andrea P
BMC Pulm Med; 2014 Jan; 14():4. PubMed ID: 24438744
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]